SAB Biotherapeutics, Inc.SABSNASDAQ
Loading
ROE: Returns DecliningContracting
Percentile Rank67
5Y CAGR-29.8%
Studio
Year-over-Year Change

Return on equity

5Y CAGR
-29.8%/yr
Long-term compound
Percentile
P67
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
1 yr
Consecutive growthContracting
PeriodValueYoY Change
20258.76%+106.7%
2024-131.33%-78.3%
2023-73.64%-22.0%
2022-60.34%-35.7%
2021-44.47%-186.2%
202051.57%-86.8%
2019389.75%-